ARCHIVES

ODAC Nixes Abraxane for Adjuvant Breast Cancer, While Genasense Falls Victim to Its Randomized Trial.

This article is from The Cancer Letter archive.

Vol. 32 No. 31 | September 8, 2006

Download PDF Visit The Full Archive

Related Articles

House Passes 2.8 Percent Increase For NCI

December 11, 2009

FDA Committee Can’t Find “Reasonable” Evidence Alkylating Agent Clinical Use Is Carcinogenic

September 10, 1976

A Biostatistics Paper Alleges Potential Harm To Patients In Two Duke Clinical Studies

October 2, 2009

Fund Squeeze Results In Percentage reductions for Renewed Program Project, Center Core Grants

April 8, 1977

DCE Board Approves Recompetition Of Two Major Contracts

October 30, 1987

Congress to hold hearings on NIH ethics, Zerhouni pledges greater transparency.

January 9, 2004